Login to Your Account



Beigene ups proposed Nasdaq IPO; counting on insider participation

By Shannon Ellis
Staff Writer

Friday, January 22, 2016

SHANGHAI – Beijing-based oncology drug developer Beigene Co. Ltd. updated plans for its Nasdaq IPO, seeking to issue 5.5 million American depository shares, representing 71.5 million ordinary shares, priced between $22 to $24 per share, which would bring in $126.5 million at the midpoint, up from the $100 million stated in its initial SEC filing in October.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription